Literature DB >> 19286635

Sphingomyelin synthase 2 is one of the determinants for plasma and liver sphingomyelin levels in mice.

Jing Liu1, Hongqi Zhang, Zhiqiang Li, Tiruneh K Hailemariam, Mahua Chakraborty, Kailiu Jiang, Daniel Qiu, Hai H Bui, David A Peake, Ming-Shang Kuo, Raj Wadgaonkar, Guoqing Cao, Xian-Cheng Jiang.   

Abstract

BACKGROUND: It has been proposed that plasma sphingomyelin (SM) plays a very important role in plasma lipoprotein metabolism and atherosclerosis. Sphingomyelin synthase (SMS) is the last enzyme for SM de novo biosynthesis. Two SMS genes, SMS1 and SMS2, have been cloned and characterized. METHODS AND
RESULTS: To evaluate the in vivo role of SMS2 in SM metabolism, we prepared SMS2 knockout (KO) and SMS2 liver-specific transgenic (LTg) mice and studied their plasma SM and lipoprotein metabolism. On a chow diet, SMS2 KO mice showed a significant decrease in plasma SM levels (25%, P<0.05), but no significant changes in total cholesterol, total phospholipids, or triglyceride, compared with wild-type (WT) littermates. On a high-fat diet, SMS2 KO mice showed a decrease in plasma SM levels (28%, P<0.01), whereas SMS2LTg mice showed a significant increase in those levels (29%, P<0.05), but no significant changes in other lipids, compared with WT littermates. Atherogenic lipoproteins from SMS2LTg mice displayed a significantly stronger tendency toward aggregation after mammalian sphingomyelinase treatment, compared with controls. Moreover, SMS2 deficiency significantly increased plasma apoE levels (2.0-fold, P<0.001), whereas liver-specific SMS2 overexpression significantly decreased those levels (1.8-fold, P<0.01). Finally, SMS2 KO mouse plasma promoted cholesterol efflux from macrophages, whereas SMS2LTg mouse plasma prevented it.
CONCLUSIONS: We therefore believe that regulation of liver SMS2 activity could become a promising treatment for atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19286635      PMCID: PMC2763553          DOI: 10.1161/ATVBAHA.109.185223

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  36 in total

1.  Rapid, specific, and sensitive measurements of plasma sphingomyelin and phosphatidylcholine.

Authors:  Mohammad Reza Hojjati; Xian-Cheng Jiang
Journal:  J Lipid Res       Date:  2005-12-21       Impact factor: 5.922

Review 2.  Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications.

Authors:  Ira Tabas; Kevin Jon Williams; Jan Borén
Journal:  Circulation       Date:  2007-10-16       Impact factor: 29.690

3.  Modulating effects of canine high density lipoproteins on cholesteryl ester synthesis induced by beta-very low density lipoproteins in macrophages. Possible in vitro correlates with atherosclerosis.

Authors:  T L Innerarity; R E Pitas; R W Mahley
Journal:  Arteriosclerosis       Date:  1982 Mar-Apr

4.  Isolation and properties of nascent lipoproteins from highly purified rat hepatocytic Golgi fractions.

Authors:  R L Hamilton; A Moorehouse; R J Havel
Journal:  J Lipid Res       Date:  1991-03       Impact factor: 5.922

5.  Putting cholesterol in its place: apoE and reverse cholesterol transport.

Authors:  Robert W Mahley; Yadong Huang; Karl H Weisgraber
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

6.  Effects of dietary supplementation with marine lipid concentrate on the plasma lipoprotein composition of hypercholesterolemic patients.

Authors:  P V Subbaiah; M H Davidson; M C Ritter; W Buchanan; J D Bagdade
Journal:  Atherosclerosis       Date:  1989-10       Impact factor: 5.162

7.  Identification of a family of animal sphingomyelin synthases.

Authors:  Klazien Huitema; Joep van den Dikkenberg; Jos F H M Brouwers; Joost C M Holthuis
Journal:  EMBO J       Date:  2003-12-18       Impact factor: 11.598

8.  Sphingomyelin synthase 2 deficiency attenuates NFkappaB activation.

Authors:  Tiruneh K Hailemariam; Chongmin Huan; Jing Liu; Zhiqiang Li; Christopher Roman; Michael Kalbfeisch; Hai H Bui; David A Peake; Ming-Shang Kuo; Guoqing Cao; Raj Wadgaonkar; Xian-Cheng Jiang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-06-19       Impact factor: 8.311

9.  Overexpression of hepatic lipase in transgenic rabbits leads to a marked reduction of plasma high density lipoproteins and intermediate density lipoproteins.

Authors:  J Fan; J Wang; A Bensadoun; S J Lauer; Q Dang; R W Mahley; J M Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-30       Impact factor: 11.205

10.  Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice.

Authors:  Tae-Sik Park; Robert L Panek; Sandra Bak Mueller; Jeffrey C Hanselman; Wendy S Rosebury; Andrew W Robertson; Erick K Kindt; Reynold Homan; Sotirios K Karathanasis; Mark D Rekhter
Journal:  Circulation       Date:  2004-11-15       Impact factor: 29.690

View more
  41 in total

Review 1.  Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics.

Authors:  Alfred H Merrill
Journal:  Chem Rev       Date:  2011-09-26       Impact factor: 60.622

2.  Effect of liver total sphingomyelin synthase deficiency on plasma lipid metabolism.

Authors:  Zhiqiang Li; Yeun-Po Chiang; Mulin He; Ke Zhang; Jiao Zheng; Weihua Wu; Jiajia Cai; Yong Chen; Guangzhi Chen; Yunqin Chen; Jibin Dong; Tilla S Worgall; Xian-Cheng Jiang
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2021-02-02       Impact factor: 4.698

3.  Functional characterization of enzymes catalyzing ceramide phosphoethanolamine biosynthesis in mice.

Authors:  Andreas Bickert; Christina Ginkel; Matthijs Kol; Katharina vom Dorp; Holger Jastrow; Joachim Degen; René L Jacobs; Dennis E Vance; Elke Winterhager; Xian-Cheng Jiang; Peter Dörmann; Pentti Somerharju; Joost C M Holthuis; Klaus Willecke
Journal:  J Lipid Res       Date:  2015-02-09       Impact factor: 5.922

4.  Pharmacological Activation of Peroxisome Proliferator-Activated Receptor {Delta} Increases Sphingomyelin Synthase Activity in THP-1 Macrophage-Derived Foam Cell.

Authors:  Dongsheng Mou; Hua Yang; Changhua Qu; Juan Chen; Chaogui Zhang
Journal:  Inflammation       Date:  2016-08       Impact factor: 4.092

5.  Regulation of plasma cholesterol esterification by sphingomyelin: effect of physiological variations of plasma sphingomyelin on lecithin-cholesterol acyltransferase activity.

Authors:  Papasani Venkata Subbaiah; Xian-Cheng Jiang; Natalia A Belikova; Buzulagu Aizezi; Zhi Hua Huang; Catherine A Reardon
Journal:  Biochim Biophys Acta       Date:  2012-02-18

6.  Selective reduction in the sphingomyelin content of atherogenic lipoproteins inhibits their retention in murine aortas and the subsequent development of atherosclerosis.

Authors:  Yifan Fan; Fujun Shi; Jing Liu; Jibin Dong; Hai H Bui; David A Peake; Ming-Shang Kuo; Guoqing Cao; Xian-Cheng Jiang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-09-02       Impact factor: 8.311

7.  Dynamic modification of sphingomyelin in lipid microdomains controls development of obesity, fatty liver, and type 2 diabetes.

Authors:  Susumu Mitsutake; Kota Zama; Hazuki Yokota; Tetsuya Yoshida; Miki Tanaka; Masaru Mitsui; Masahito Ikawa; Masaru Okabe; Yoshikazu Tanaka; Tadashi Yamashita; Hiroshi Takemoto; Toshiro Okazaki; Ken Watanabe; Yasuyuki Igarashi
Journal:  J Biol Chem       Date:  2011-06-13       Impact factor: 5.157

8.  Postprandial changes in high density lipoproteins in rats subjected to gavage administration of virgin olive oil.

Authors:  Roberto Martínez-Beamonte; María A Navarro; Sergio Acin; Natalia Guillén; Cristina Barranquero; Carmen Arnal; Joaquín Surra; Jesus Osada
Journal:  PLoS One       Date:  2013-01-29       Impact factor: 3.240

9.  Lithium Hydroxide Hydrolysis Combined with MALDI TOF Mass Spectrometry for Rapid Sphingolipid Detection.

Authors:  Anh Tran; Liting Wan; Zhenbo Xu; Janette M Haro; Bing Li; Jace W Jones
Journal:  J Am Soc Mass Spectrom       Date:  2020-10-30       Impact factor: 3.109

10.  PPARα-dependent exacerbation of experimental colitis by the hypolipidemic drug fenofibrate.

Authors:  Yunpeng Qi; Changtao Jiang; Naoki Tanaka; Kristopher W Krausz; Chad N Brocker; Zhong-Ze Fang; Bryce X Bredell; Yatrik M Shah; Frank J Gonzalez
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-07-17       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.